Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma

J. Shamash, J. Walewski, J. Apostolidis, A. M. Wilson, J. M. Foran, R. K. Gupta, A. Z.S. Rohatiner, S. M. Kelsey, T. A. Lister

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: Although lymphoid malignancies are generally chemosensitive, relapse is common. The use of high-dose therapy can make subsequent cytotoxic therapy intolerable. There is a need to develop regimens with low acute toxicity which are suitable for use in patients post-high dose therapy and following the failure of standard protocols. Patients and methods: Twenty-six patients with lymphomas, fifteen of whom had received high-dose therapy, were treated with a novel regimen consisting of low-dose lomustine, chlorambucil, daily subcutaneous bleomycin, vincristine and methotrexate with dexamethasone on an eight-week cycle (LBCMVD-56). A median of three cycles was given. Results: The overall response rate at 12 weeks was 67% (21% complete remission (CR)) with a median overall survival of 13 months. A symptomatic response was seen in 72%. Previous high-dose therapy did not compromise the response rate. Toxicity was acceptable with grade 3-4 haematological toxicity seen in 27% of cycles, gastrointestinal toxicity seen in 11% and pulmonary toxicity seen in 8%. Thirty-one percent of patients required hospitalisation at some point during this treatment most commonly for neutropenic sepsis. Conclusions: LBCMVD-56 is an inexpensive, outpatient-based regimen with low acute toxicity and a high response rate in this heavily pre-treated group of patients.

Original languageEnglish (US)
Pages (from-to)857-860
Number of pages4
JournalAnnals of Oncology
Issue number7
StatePublished - 2000


  • Low-dose continuous chemotherapy
  • Lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma'. Together they form a unique fingerprint.

Cite this